ArticleArthritis research & therapy2025
Regulation of fibroblast-like synoviocyte function by cadherin 6 in rheumatoid arthritis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting the cytokine-epigenetic axis: a new paradigm and prospects for disease treatment.European cytokine network · 2026Review
- Beyond inflammation: siRNA strategies for precision targeting in rheumatological disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Anti-inflammatory, analgesic, and anti-immune-mediated polyarthritis activities of topically applied polarity fractions ofFrontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCadherins (CDH), such as CDH11, are glycoprotein adhesion molecules contributing to cell-cell interactions in health and disease. CDH11 has demonstrated important functions in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). In transcriptome expression studies, we observed that Cadherin 6 (CDH6) expression was higher in RA compared to osteoarthritis (OA). CDH6 is associated with cancer progression, but little information is known on the role of CDH6 in RA. The present study investigates CDH6 expression, regulation, function in FLS, and distribution in RA synovia.
methodsSynovial tissue and FLS were obtained from RA or OA patients undergoing joint replacement. CDH6 epigenetic marks and expression in RA and OA FLS were evaluated using public databases. CDH6 expression was determined by RT-PCR, Western blot, and immunostaining. RA and OA FLS were stimulated with cytokines and growth factors, and CDH6 mRNA expression was determined. CDH6 was silenced using siRNA, and the effect on migration, cell growth, apoptosis, autophagy, cell cycle, and signaling was studied.
resultsIn our analysis of cadherin family expression, CDH6 expression was higher in RA than OA FLS. This was associated with differential chromatin accessibility and histone marks in the CDH6 promoter of RA FLS. H3K27ac was identified as an important regulator of CDH6 expression in RA FLS based on experiments using histone deacetylase inhibitors. TGFß, but not IL-1β, TNF, IL-17A, IFNγ, IL-6, or PDGF, increased CDH6 expression of cultured RA FLS. CDH6 knockdown significantly decreased RA FLS migration and cell growth. The latter was associated with increased apoptosis in CDH6 deficient FLS. Immunofluorescence showed CDH6 protein distribution in the membrane, perinuclear, and nuclear regions of cultured FLS. In RA synovial tissue, CDH6 expression was noted in FLS and macrophages within the lining and sublining regions.
conclusionsCDH6 expression is elevated in RA FLS due to epigenetic and local conditions of synovitis promoting migration, survival and cell growth, which are characteristic features of aggressive RA FLS. The intracellular distribution suggests additional functions beyond adhesion and homotypic aggregation, such as signaling and gene regulation. These data suggest CDH6 contributes to RA pathogenesis by influencing pathologic FLS behavior and could be a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.